LEXARIA BIOSCIENCE CORP. Finance Lease, Right-of-Use Asset, Amortization
LEXARIA BIOSCIENCE CORP. (LEXX) reported Finance Lease, Right-of-Use Asset, Amortization of $38.60 thousand for the 12-month period ending 2022-08-31, per its 10-K filed 2022-11-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2022-11-28
- LEXARIA BIOSCIENCE CORP. finance lease, right-of-use asset, amortization for fiscal 2022 was $38.60K, a 7.58% increase from fiscal 2021.
- LEXARIA BIOSCIENCE CORP. finance lease, right-of-use asset, amortization for fiscal 2021 was $35.88K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|
| 2022-08-31 | $38.60K 10-K · filed 2022-11-28 |
| 2021-08-31 | $35.88K 10-K · filed 2022-11-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |